Zobrazeno 1 - 10
of 93
pro vyhledávání: '"M, Hedenus"'
Autor:
J, Szebeni, S, Fishbane, M, Hedenus, S, Howaldt, F, Locatelli, S, Patni, D, Rampton, G, Weiss, J, Folkersen
Publikováno v:
British journal of pharmacology. 172(21)
Intravenous (IV) iron therapy is widely used in iron deficiency anaemias when oral iron is not tolerated or ineffective. Administration of IV‐iron is considered a safe procedure, but severe hypersensitivity reactions (HSRs) can occur at a very low
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2dfce356de24d7d0ece9ad1df4d2e6ea
https://pubmed.ncbi.nlm.nih.gov/26265306
https://pubmed.ncbi.nlm.nih.gov/26265306
Autor:
K Wallman, G Tjønnfjord, C M Stolt, M Hedenus, D Heldal, E Hippe, F Albertioni, Stein A. Evensen, Gunnar Juliusson, Claes Malm
Publikováno v:
Journal of Clinical Oncology. 13:989-995
PURPOSE To evaluate the clinical efficacy and safety of 2-chlorodeoxyadenosine (CdA) when administered by subcutaneous injection to patients with symptomatic hairy cell leukemia (HCL), and to evaluate predictive factors for response. PATIENTS AND MET
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99c3f0adf146f6c05c76425c65f961e0
https://doi.org/10.1200/jco.1995.13.4.989
https://doi.org/10.1200/jco.1995.13.4.989
Publikováno v:
International Journal of Gynecology & Obstetrics. 119:S858-S859
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0b56292ec2251654acafff3d00372e9
https://doi.org/10.1016/s0020-7292(12)62191-2
https://doi.org/10.1016/s0020-7292(12)62191-2
Autor:
Anders Österborg, M. Hedenus, Yvonne Brandberg, G. Iosava, D. Messinger, K. Abdulkadyrov, V. Molostova
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20(10)
PURPOSE: To investigate the effect of recombinant human erythropoietin (epoetin beta) on anemia, transfusion need, and quality of life (QOL) in severely anemic patients with low-grade non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd5a2331b5394c69dd35fe0aea77535f
https://pubmed.ncbi.nlm.nih.gov/12011126
https://pubmed.ncbi.nlm.nih.gov/12011126
Autor:
H, Brincker, J, Westin, N, Abildgaard, P, Gimsing, I, Turesson, M, Hedenus, J, Ford, A, Kandra
Publikováno v:
British journal of haematology. 101(2)
In order to study whether oral bisphosphonate therapy might prevent or reduce skeletal-related morbidity in patients with newly diagnosed multiple myeloma who required chemotherapy, 300 patients were included in a randomized multi-centre trial. Patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dfa0f0a0163a5698ab38962c006c270d
https://pubmed.ncbi.nlm.nih.gov/9609523
https://pubmed.ncbi.nlm.nih.gov/9609523
Publikováno v:
Lakartidningen. 90(24)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::26184753d2d4c7f3237929208844e3f9
https://pubmed.ncbi.nlm.nih.gov/8316010
https://pubmed.ncbi.nlm.nih.gov/8316010
Autor:
P, Gimsing, O W, Bjerrum, E, Brandt, J, Ellegaard, S A, Evensen, M M, Hansen, M, Hedenus, E, Hippe, N, Keldsen, I, Palva
Publikováno v:
British journal of haematology. 77(1)
In a phase II study, patients with refractory myelomatosis were treated with a combination chemotherapy (NOP regimen): mitoxantrone (bolus injection of 4 mg/m2 on days 1-4), vincristine (continuous infusion of 0.4 mg/24 h on days 1-4) and prednisone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d68ef58f85d6dcd9ce9682cc1f373f9b
https://pubmed.ncbi.nlm.nih.gov/1772791
https://pubmed.ncbi.nlm.nih.gov/1772791
Autor:
M Hedenus, G Birgegård, P Näsman, L Ahlberg, T Karlsson, B Lauri, J Lundin, G Lärfars, A Österborg
Publikováno v:
Leukemia. 22:462-462
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69bffdab65937d95fc4e7208e45d5037
https://doi.org/10.1038/sj.leu.2405094
https://doi.org/10.1038/sj.leu.2405094
Autor:
M. Hedenus, G. Birgegård
Publikováno v:
Medical Oncology; Mar2009, Vol. 26 Issue 1, p105-115, 11p
Publikováno v:
Cancer treatment reports. 71(12)
Thirty-five patients with non-Hodgkin's lymphoma, who had relapsed from or failed prior cytotoxic regimens including doxorubicin, received mitoxantrone at a dose of 14 mg/m2 iv every 3 weeks. According to the working formulation, 18, 15, and two pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2ce80a306210810008cc9083bf9fe6a8
https://pubmed.ncbi.nlm.nih.gov/3690531
https://pubmed.ncbi.nlm.nih.gov/3690531